Trodelvy Improves Progression-Free Survival for HR+, HER2- MBC

moderators

moderators Posts: 9,586

June 2022 edited June 2022 in Stage IV/Metastatic Breast Cancer ONLY

Trodelvy Slightly Improves Progression-Free Survival for Pre-treated Metastatic Hormone Receptor-Positive, HER2-Negative Breast Cancer
June 8, 2022
Trodelvy (chemical name: sacituzumab govitecan-hziy) slightly improved progression-free survival in people diagnosed with metastatic hormone receptor-positive, HER2-negative breast cancer previously treated with hormonal therapy, a CDK4/6 inhibitor, and multiple lines of chemotherapy. Read more...

0

Categories

Join Us on Zoom: Upcoming virtual support groups. Read more...

Share more about you! Fill out your NEW profile.